esophageal cancer
Conditions
Interventions
experimental group:Complete enteral nutrition (Ensure)
Control group:Routine diet before operation via vein, and Intravenous supplementation of parenteral nutrition with the same calorific value in the experimental group, Combined oral and parenteral nutr
Sponsors
Sichuan Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Subject is male or female, between 18 and 75 years old (inclusive); 2. Subject has clinical or radiological diagnosis of esophageal cancer (stage I, II, III) scheduled to undergo surgical resection; 3. Subjects did not receive radiotherapy; 4. Subjects are malnourished or have malnutrition risk (PG-SGA score> = 4 points or NRS-2002> = 3 points); 5. Female subjects are not pregnant or at least six weeks postpartum and non-lactating. A pregnancy test at Screening will be required in females of childbearing potential to confirm non-pregnancy status; 6. Subject is willing to comply with the study protocol, able and willing to consume study product according to the protocol; 7. Subject has an expected life expectancy = 3 months; 8. Subject has voluntarily signed and dated the informed consent form (ICF), approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC) prior to any participation in the study.
Exclusion criteria
Exclusion criteria: 1. Subject has severe renal and liver dysfunction reflected by blood chemistries according to lab results in medical records; 2. Subject has cardiac insufficiency (in the opinion of study physician); 3. Subject has type I or type II diabetes (per medical history and admission diagnosis, in the opinion of study physician); 4. Subject has severe nausea, vomiting and/or uncontrolled diarrhea/steatorrhoea within the previous week (per reported history or in the opinion of study physician); 5. Subject has known dementia, brain metastases, eating disorder, history of significant neurological or psychiatric disorder, or stated undergoing psychiatric treatment for mental illness; 6. Subject has known history of allergy or intolerance to any ingredient in the investigational product; 7. Subject is currently or has participated in any clinical trial that has not been approved by Abbott.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seralbumin; | — |
Countries
China
Contacts
Public ContactLiu Guangyuan
Outcome results
None listed